Old Web
English
Sign In
Acemap
>
authorDetail
>
Xiugao Yang
Xiugao Yang
open label
Medicine
Oncology
Internal medicine
in patient
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase II clinical trial.
2021
Journal of Clinical Oncology
Zhong Zheng
Yuhuan Gao
Yongping Song
Ying Qian
Hongmei Jing
Tingbo Liu
Lei Zhang
Xiuhua Sun
Yang Zhang
Lie Lin
Hongxia Yao
Huilai Zhang
Jie Jin
Xiugao Yang
Jing Yuan
Xin Yan
Wenjuan Peng
Bin Bai
Hengyi Zhang
Weili Zhao
Show All
Source
Cite
Save
Citations (0)
Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.
2020
Journal of Clinical Oncology
Jin Li
Huiping Li
Shukui Qin
Ye Guo
Xu Liang
Junli Xue
Wei Peng
Xiaoxiao Ge
Changxing Xie
Xiugao Yang
Tao Li
Jinglin Xu
Li Feng
Zhufeng Wu
Guanxi Xiao
Peng Zhang
Tianyi Zhang
Chenchen Wang
Baoxia Zhang
Zijian Hu
Show All
Source
Cite
Save
Citations (1)
A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC).
2020
Journal of Clinical Oncology
Jian Li
Lin Shen
Jifang Gong
Zhi Peng
Dan Liu
Changsong Qi
Jiajia Yuan
Rong Hu
Xiugao Yang
Tao Li
Dongxue Fu
Ruirui Yang
Li Feng
Peng Zhang
Xin Chen
Jing Yuan
Yuanyuan Liu
Zhufeng Wu
Ye Cao
Shulin Zhong
Show All
Source
Cite
Save
Citations (1)
1